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Abstract
Background: Paclitaxel-eluting stents decrease angiographic and clinical restenosis following percutaneous
coronary intervention compared to bare metal stents. TAXUS Element is a third-generation paclitaxel-eluting stent
which incorporates a novel, thinner-strut, platinum-enriched metal alloy platform. The stent is intended to have
enhanced radiopacity and improved deliverability compared to other paclitaxel-eluting stents. The safety and
efficacy of the TAXUS Element stent are being evaluated in the pivotal PERSEUS clinical trials.
Methods/Design: The PERSEUS trials include two parallel studies of the TAXUS Element stent in single, de novo
coronary atherosclerotic lesions. The PERSEUS Workhorse study is a prospective, randomized (3:1), single-blind, non-
inferiority trial in subjects with lesion length ≤28 mm and vessel diameter ≥2.75 mm to ≤4.0 mm which compares
TAXUS Element to the TAXUS Express
2 paclitaxel-eluting stent system. The Workhorse study employs a novel
Bayesian statistical approach that uses prior information to limit the number of study subjects exposed to the
investigational device and thus provide a safer and more efficient analysis of the TAXUS Element stent. PERSEUS
Small Vessel is a prospective, single-arm, superiority trial in subjects with lesion length ≤20 mm and vessel
diameter ≥2.25 mm to <2.75 mm that compares TAXUS Element with a matched historical bare metal Express
stent control.
Discussion: The TAXUS PERSEUS clinical trial program uses a novel statistical approach to evaluate whether design
and metal alloy iterations in the TAXUS Element stent platform provide comparable safety and improved
procedural performance compared to the previous generation Express stent. PERSEUS trial enrollment is complete
and primary endpoint data are expected in 2010. PERSEUS Workhorse and Small Vessel are registered at http://
www.clinicaltrials.gov, identification numbers NCT00484315 and NCT00489541.
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Drug-eluting stents, including paclitaxel-eluting stents,
have been shown to reduce angiographic restenosis and
the need for repeat revascularization following coronary
angioplasty compared to bare metal stents [1,2]. How-
ever, repeat revascularization is still required in approxi-
mately 7-10% of patients (versus 20-25% with bare metal
stents) [3]. It has been proposed that the thickness of
stent struts may impact the ability of the stent to reduce
restenosis. Compared to first generation stents with strut
thicknesses of approximately 130-150 μm, stents with
thinner stent struts (80-100 μm) have been associated
with a lower late luminal loss and less neointimal volume
obstruction after stenting, possibly as a result of less
stent-induced arterial injury and inflammation [4,5].
Thinner stent struts also facilitate deliverability through
tortuous vessel anatomy. However, the development of
thinner struts with 316L stainless steel limits both radio-
graphic visualization (ie, radiopacity), which is required
to ensure proper stent placement, and the necessary
radial strength for adequate stent expansion, particularly
in resistant fibrocalcific target lesions [6].
The TAXUS Element paclitaxel-eluting coronary stent
uses the same polymer and has similar paclitaxel release
kinetics as the earlier TAXUS Express [1,7,8] and
TAXUS Liberté [2,9-11], 9-11 316L stainless steel stent
systems, but employs a new 81 μm platinum chromium
alloy in a design intended to improve deliverability,
increase radiopacity, and maintain low stent recoil when
compared with previous TAXUS stent designs. The
PERSEUS program evaluates the TAXUS Element stent
for the treatment of single de novo atherosclerotic
lesions using a novel Bayesian statistical approach to
increase efficiency.
Methods/Design
Device Description
The TAXUS Element stent is a novel, balloon-expand-
able, 81 μm, platinum chromium alloy stent pre-
mounted on a high-pressure delivery balloon. The phar-
macological agent, paclitaxel, is incorporated into a tri-
block polymer matrix and applied to the surface of the
stent to provide controlled release of available paclitaxel
(see Appendix A for a detailed description of TAXUS
Element and comparison to previous platforms).
Study Designs
The TAXUS PERSEUS Clinical Trial Program evaluates
the TAXUS Element paclitaxel-eluting stent system for
the treatment of single, de novo atherosclerotic lesions
in two parallel studies (Figure 1).
The PERSEUS Workhorse (WH) trial
PERSEUS WH is a prospective, randomized, single-
blind, non-inferiority trial which employs a 3:1
randomization to the TAXUS Element or the TAXUS
Express paclitaxel-eluting stents respectively. Subjects
with target lesion length ≤28 mm and reference vessel
diameter (RVD) ≥2.75 mm to ≤4.0 mm were considered
for enrollment. Additional inclusion and exclusion cri-
teria are given in Appendix B. Subjects were randomized
after successful predilatation of the target lesion and
were considered to be enrolled at the time of randomi-
zation. The randomization schedules were computer-
generated using a pseudo-random number generator
and stratified both by clinical site and by the presence
or absence of medically treated diabetes. The number of
diabetic subjects was capped at 350. In total, 1264 sub-
jects were enrolled at 90 clinical sites in the United
States, Australia, New Zealand, and Singapore (see
Acknowledgements), of whom 330 subjects were ran-
domly assigned to protocol-mandated 9-month angio-
graphic follow-up (angiographic subset). The primary
endpoint is the rate of target lesion failure (TLF) at 12
months post-index procedure. In-segment percent dia-
meter stenosis at 9 months post-index procedure as
measured by quantitative coronary angiography (QCA)
is the secondary endpoint. Additional clinical and angio-
graphic endpoints in both the WH and Small Vessel
studies include target vessel revascularization (TVR),
major adverse cardiac events (MACE), stent thrombosis,
and technical and procedural success, as well as angio-
graphic late loss and binary restenosis.
PERSEUS Small Vessel (SV) Trial
PERSEUS SV is a prospective, single-arm, superiority
trial that compares the TAXUS Element stent to a
matched bare metal (Express) historical control group
garnered from the TAXUS V trial. The control group
comprised 125 intent-to-treat subjects with RVD ≥2.25
to <2.75 mm and lesion length ≤20 mm of whom 108
subjects had QCA at 9-month follow-up. A total of 224
subjects from 28 United States sites were enrolled. All
subjects in PERSEUS SV are required to undergo a 9-
month angiographic assessment. The primary endpoint
is in-stent late loss by QCA on 9-month angiographic
follow-up and the key secondary endpoint is TLF at 12
months. Additional clinical and angiographic endpoints
are similar to the PERSEUS WH study as noted above.
Endpoint Definitions
TLF is defined as any ischemia-driven revascularization
of the target lesion (TLR), myocardial infarction (MI;
both Q-wave and non-Q-wave) related to the target ves-
sel, or cardiac death related to the target vessel. If rela-
tionship to the target vessel could not be determined
with certainty, the event was assumed to be related to
the target vessel. MACE is defined as MI, TVR, or car-
diac death. Stent thrombosis is defined per historical
Boston Scientific Corporation protocol definitions (see
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tium definition [12]. Additional clinical and angio-
graphic endpoint definitions are given in Appendix C.
Follow-up Schedule
For both studies, clinical endpoint measurements were
conducted in-hospital and at 30 days, and are planned
at 9 months, 12 months, 18 months, 2 years, 3 years, 4
years, and 5 years. Angiographic follow-up at 9 months
is planned for subjects randomized to the angiographic
subset in the PERSEUS WH study and for all subjects in
PERSEUS SV. Starting with the 18-month visit, follow-
up will be limited to those study subjects who actually
received a study stent (TAXUS Element or TAXUS
Express).
Antiplatelet and Other Concomitant Medical Therapy
Treatment with aspirin and clopidogrel (or ticlopidine)
is required for both PERSEUS studies in compliance
with the ACC/AHA/SCAI Guidelines for percutaneous
coronary intervention (PCI) [13]. Aspirin ≥300 mg was
administered orally at least 1 hour prior to catheteriza-
tion and a clopidogrel oral loading dose of ≥300 to 600
mg was administered (preferably ≥6h o u r sp r i o rt ot h e
procedure, but no later than 2 hours after completion of
the index procedure). During the procedure,
Figure 1 PERSEUS WH and PERSEUS SV Study Schematic.
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to maintain an activated clotting time ≥250 seconds.
Alternatively, enoxaparin, bivalirudin or other proce-
dural antithrombotics could be administered per local
standard of practice. Abciximab, eptifibatide, and tirofi-
ban could be administered at the discretion of the inves-
tigator. Clopidogrel at 75 mg orally daily was required
for at least 6 months and ideally up to 12 months in
subjects not at high risk of bleeding consistent with the
ACC/AHA/SCAI Guidelines for PCI in effect at the
time study enrollment began. Five months after the start
of study enrollment, the PCI guidelines were revised to
recommend 12 months of clopidogrel therapy in all
patients receiving drug-eluting stents [13]. In case of
allergy or intolerance to clopidogrel, ticlopidine 250 mg
orally twice daily was prescribed. Daily aspirin therapy
was mandated concomitantly with clopidogrel or ticlopi-
dine and continued indefinitely.
Criteria for Multiple and Staged Interventions
Only one target lesion segment, treatable by a single
stent, was to be considered the target lesion. If separate
lesions in 2 different native coronary arteries were eligi-
ble, the operator was to decide which lesion would be
treated as the target lesion prior to treating any lesion(s)
or vessel(s). The assumed culprit lesion was selected as
the target lesion (defined as the lesion most likely
responsible for a clinical event based on evidence of
ischemia or the lesion with greatest percent diameter
stenosis on visual estimate). Treatment of one lesion in
a single non-target vessel during the index procedure
was allowed by protocol prior to treatment of the target
lesion. Treatment of the non-study lesion could not
require additional unplanned stents, and must have
been successful angiographically (see Appendix C) for
the subject to be eligible for enrollment into the study.
Staged PCI or subsequent planned coronary artery
bypass graft procedures were not allowed post-index
procedure.
Angiographic Follow-up
Angiographic follow-up is required at 9 months in the
angiographic subset of PERSEUS WH and in all PER-
SEUS SV subjects. Central analysis of all angiographic
studies will be performed by an Angiographic Core
Laboratory (Beth Israel Deaconess Medical Center, Bos-
ton, MA) using standard qualitative morphologic criteria
[14] identical to those used in the TAXUS Express and
TAXUS Liberté clinical trials [15].
Statistical Analysis Plan for the Primary Endpoint
PERSEUS WH
For the primary endpoint analysis, Bayesian hierarchical
modeling will be used to determine if the 12-month
TLF rate for the TAXUS Element stent is non-inferior
to the 12-month TLF rate for the TAXUS Express
2
paclitaxel-eluting stent system. The hierarchical model
will be used to estimate the difference in the 12-month
TLF rate between the TAXUS Element and TAXUS
Express devices. This hierarchical model involves the
TLF rates observed for TAXUS Element and TAXUS
Express in patients enrolled in PERSEUS WH, as well as
rates observed in data conditionally borrowed from
TAXUS IV and V patients (under the Bayesian frame-
work, as described below).
Bayesian methods differ from the more conventional
frequentist methods in that they can utilize prior infor-
mation, potentially increasing the precision of analyses
[16]. While frequentist methods also use prior data in
trial planning for sample size and power calculations,
the evidence for or against the null hypothesis comes
solely from the current trial. By utilizing the prior infor-
mation in assessing trial endpoints, the Bayesian
approach may allow for a smaller sample size, thereby
minimizing the number of patients exposed to an inves-
tigational drug or device during its evaluation. Bayesian
analyses may be interpreted in a more intuitive way
than frequentist analyses because they treat the para-
meter of interest as a random variable rather than as a
fixed unknown value. Specifically, Bayesian methods
provide a posterior probability that a statement is true
or false given the prior information and the observed
data, whereas the frequentist P value provides the prob-
ability of observing data as or more extreme than that
observed assuming the null hypothesis is true. The
Bayesian approach has been supported by the US Food
and Drug Administration’s (FDA) Center for Devices
and Radiological Health for medical device clinical trials
when the prior data utilized come from robust clinical
studies [17,18]. Bayesian methods were chosen for PER-
SEUS WH in order to utilize extensive prior data on the
TAXUS Express stent [19], and thus reduce the number
of study subjects, particularly in the control arm. In the
PERSEUS WH trial, historical TAXUS Express stent
data from the TAXUS IV and TAXUS V trials [1,7] may
be borrowed under certain conditions to augment data
from the TAXUS Express control group, using subjects
who had similar target lesion characteristics (lesion
length ≤28 mm, RVD 2.75 mm - 4.0 mm) as those
enrolled in the PERSEUS WH study. The observed 12-
month TLF rates in these historical cohorts was 8.2%
(44/535) for TAXUS IV and 10.9% (33/304) for TAXUS
V. Historical control data will only be borrowed if the
observed 12-month TLF rate in the TAXUS Express
control group enrolled in PERSEUS WH exceeds 8.0%.
If the observed TLF rate for PERSEUS WH subjects
treated with the TAXUS Express stent is ≤8.0%, histori-
cal data will not be borrowed as doing so would raise
the TLF rate in TAXUS Express stent subjects in the
non-inferiority comparison and potentially bias the ana-
lysis in favor of the TAXUS Element stent. This design
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borrowing. The weight of the historical data will depend
on how closely the results from the concurrent control
match those from the historical controls. If data are bor-
rowed, data from approximately 119 patients (if 12%
TLF rate observed) to 199 patients (if 9% TLF rate
observed) will be “effectively” borrowed from the histori-
cal control, as discussed by Malec et al, 2001 [20]. Based
on discussions with the US FDA, a non-inferiority mar-
gin (Δ) of 4.1% was chosen and non-inferiority of the
TAXUS Element stent will be accepted if the Bayesian
posterior probability (θ1 - θ2 < 0.041 | data) is at least
0.95, where θ1 is the 12-month TLF rate for TAXUS
Element and θ2 is the 12-month TLF rate for TAXUS
Express. This non-inferiority margin preserves at least
half of the treatment difference observed between
TAXUS Express and the lesion-diameter-matched bare
metal Express stent control in the combined TAXUS IV
and V trials [1,7]. This difference in TLF was deemed to
be clinically indistinguishable from a treatment choice
perspective and is similar to non-inferiority margins
used in other studies comparing DES [21,22]. The sam-
ple size of 1264 subjects (which is expected to result in
1200 evaluable subjects assuming 5% attrition) was
determined through simulations based on hierarchical
modeling. Although power and type I error do not
apply to PERSEUS WH in the frequentist sense, this
sample size was selected because it was the minimum
sample size required to give approximately an 80% prob-
ability of correctly concluding non-inferiority (over a
range of assumed TAXUS Express TLF rates from 6%
to 12%) if the TAXUS Element TLF rate is indeed non-
inferior to the TAXUS Express TLF rate.
PERSEUS SV
For the PERSEUS SV study, a 2-sided t-test will be used
to determine if the 9-month in-stent late loss observed
for the TAXUS Element stent is superior to that
observed for the bare metal Express stent historical con-
trol subjects in the TAXUS V trial. The null hypothesis
that the true difference in means (TAXUS Element -
b a r em e t a lE x p r e s s )i se q u a lt oz e r ow i l lb et e s t e d
against the two-sided alternative that the true difference
in means is different from zero. The sample size was
calculated for a two-group test of means using nQuery
Advisor® Version 5 (Statistical Solutions Ltd., Saugus,
Massachusetts, USA). The expected 9-month in-stent
late loss for the TAXUS Element stent is 0.55 mm and
the 9-month in-stent late loss for the Express stent is
the observed mean (0.77 mm) from the TAXUS V study
in subjects with visual estimate RVD ≥2.25 mm to <2.75
mm and lesion length ≤20 mm [7]. The common stan-
dard deviation is assumed to be 0.6 mm, which is
derived from the TAXUS V Express stent cohort. Given
at w o - s i d e da of 0.05, 190 TAXUS Element stent
subjects will provide 85% power to reject the null
hypothesis if it is indeed false. Further allowance for
approximately 15% attrition based on a QCA endpoint
resulted in a study enrollment target of 224 subjects.
All frequentist statistical analyses will be done using
The SAS System Version 8.2 software or above (SAS
Institute Inc., North Carolina, USA). Software for the
Bayesian hierarchical modeling was developed by Profes-
sor Ming-Hui Chen (University of Connecticut) and was
written using the Fortran 90 language and compiled
with the Intel Visual Fortran Compiler Professional Edi-
tion for Windows with IMSL Version 10.1 or above
(Intel Corporation, Santa Clar a ,C a l i f o r n i a ,U S A ) .T h i s
software was also used to run simulations of sample
size, power and type I error based on the hierarchical
models and specialized Gibbs sampling algorithms.
Study Organization and Ethical Considerations
An independent clinical events committee will adjudi-
cate all reported events of stent thrombosis and MACE.
An independent data monitoring committee is responsi-
ble for oversight of all reported adverse events and
aggregate safety data to monitor for incidence of MACE
and other trends that may warrant modification or ter-
mination of the trials. PERSEUS study organization and
oversight committee membership are listed in the
acknowledgements.
The Institutional Review Board or Ethics Committee
at each participating center approved the study protocol
and all subjects provided written informed consent. The
protocols and consent forms were consistent with the
International Conference on Harmonisation Guidance
for Industry E6 Good Clinical Practice, the Declaration
of Helsinki, EN ISO 14155-1 and EN ISO 14155-2, and
all local regulations, as appropriate. The PERSEUS study
protocols were approved by the US FDA under Investi-
gational Device Exception number G060237.
Limitations of Study Design
The comparator controls for PERSEUS were chosen
based on the commercially available stents at the time
of study enrollment. Since that time, a next generation
paclitaxel-eluting stent (TAXUS Liberté) and 2 dedi-
cated small vessel paclitaxel-eluting stents (TAXUS
Express Atom and TAXUS Liberté Atom) have been US
FDA approved. Thus, the PERSEUS comparator groups
do not represent the most recently available paclitaxel-
eluting stents. Although the formal statistical hypotheses
were based on TAXUS Express and Express bare metal
stent, the PERSEUS results will need to be interpreted
in the context of more recent DES studies.
In addition, the study design includes comparisons to
historical controls. In PERSEUS, use of historical data
could contribute to bias as a result of differences in
patient complexity or patterns of treatment between
PERSEUS and historical controls. For PERSEUS WH,
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the observed TLF rate in the TAXUS Express concur-
rent control is similar to the TLF rate in the historical
TAXUS Express control. This conditional borrowing
results in a more conservative test and also minimizes
the likelihood that differences between the concurrent
and historical controls will bias the non-inferiority
comparison.
Discussion
The TAXUS Element paclitaxel-eluting stent incorpo-
rates a new metal alloy in a novel design, intended to
facilitate deliverability and improve radiopacity relative to
the earlier generation TAXUS Express
2 and TAXUS Lib-
erté stent systems. The safety and efficacy of the TAXUS
Element stent are being studied in the PERSEUS clinical
trial program, which evaluates the TAXUS Element stent
in comparison with either thef i r s tg e n e r a t i o nT A X U S
Express stent (WH) or a bare metal Express stent (SV).
The PERSEUS WH study employs a novel Bayesian sta-
tistical design that uses data from prior TAXUS Express
studies to increase power while maintaining acceptable
type I error and limiting the number of subjects treated
in the study. Enrollment is complete in both studies and
primary endpoint data are expected in 2010.
List of Abbreviations
ACC: American College of Cardiology; AHA: American
Heart Association; FDA: US Food and Drug Administra-
tion; MACE: Major Adverse Cardiac Events (MI, TVR,
Cardiac Death); MI: Myocardial Infarction; PCI: Percuta-
neous Coronary Intervention; QCA: Quantitative
Coronary Angiography; RVD: Reference Vessel Dia-
meter; SCAI: Society for Cardiovascular Angiography
and Interventions; SV: Small Vessel (PERSEUS Small
Vessel Study); TLF: Target Lesion Failure; TLR: Target
Lesion Revascularization; TVR: Target Vessel Revascu-
larization; WH: Workhorse (PERSEUS Workhorse
Study).
Appendices
Appendix A: TAXUS Element Stent Design and Preclinical
Testing TAXUS Element Stent Design
TAXUS Element incorporates several design changes
compared with the TAXUS Express or TAXUS Liberté
stent platforms (Table 1). TAXUS Element uses a novel
platinum chromium alloy to replace the 316L stainless
steel used in previous generation TAXUS stents. This
platinum chromium alloy provides increased radial
strength and fracture resistance to allow thinner stent
struts (Figure 2A). Nominal elemental compositions by
weight of the platinum chromium alloy in comparison
to other materials are given in Table 2.
The material properties of platinum chromium, in
conjunction with the Element stent design, are expected
to provide stent recoil that is similar to 316L stainless
steel stent platforms and reduced compared with cur-
rent cobalt chromium alloy stent platforms. Deployment
recoil of the Element stent is 3.6 [95% CI 3.2-4.0] (n =
15) compared to 2.8 [95% CI 2.5-3.1] (n = 25) for the
Express stent at a deployment diameter of 3.0 mm, as
measured in accordance with ASTM standards [23]. In
contrast, deployment recoil of current cobalt chromium
stents (Xience and Endeavor) has been measured to be
Table 1 Stent Platform Comparison
Component/Characteristic TAXUS Express TAXUS Liberté TAXUS Element Impact of Change
Stent Material 316L Stainless Steel 316L Stainless Steel Platinum Chromium
Alloy
Higher strength & radiopacity
Drug Paclitaxel N/A
Polymer Slow-Release Translute polymer N/A
Strut Width 71 μm-91 μm7 6 μm-94 μm6 1 μm-89 μm Greater flexibility, Lower profile,
Reduced inflammation Strut Thickness* 132 μm9 7 μm8 1 μm-86 μm
Nominal Balloon Pressure 9 atm 9 atm for ≤2.50 mm
8 atm ≥2.75 mm
11 atm Optimized for stent/balloon
configuration
Balloon Rated Burst Pressure 18 atm (2.25-4.0 mm)
16 atm (4.5-5.0 mm)
18 atm (2.0-4.0 mm)
16 atm (4.5-5.0 mm)
18 atm (2.0-2.25 mm)
16 atm (2.5-5.0 mm)
Surface-to-Artery Ratio
† 2.25mm: 20.0% 2.25 mm: 18.6% 2.25 mm: 17.8% More uniform drug delivery across
stent diameters 2.50 mm: 18.9% 2.50 mm: 17.6% 2.50 mm: 17.6%
3.00 mm: 15.2% 3.00 mm: 19.5% 3.00 mm: 16.4%
4.00 mm: 14.6% 4.00 mm: 17.1% 4.00 mm: 15.2%
* Strut thickness is 86 μm for the 4.00 mm model, and 81 μm for all other models.
† Surface-to-Artery Ratio (SAR) is the percentage of artery wall area covered by outer surface area of the stent. Large values imply a greater surface area of drug
coating in direct contact with the vessel and by inference, a larger dose delivered to the local arterial tissue. SAR can vary significantly by diameter for the same
stent model. Increasing the number of stent models covering a diameter range decreases the variation of SAR by minimizing the stent’s working range.
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= 7), respectively, at a deployment diameter of 3.0 mm.
Several factors correlate with or contribute to radiopa-
city (x-ray attenuation) of a material, and material den-
sity provides a direct relative comparison of stent
radiopacity. Density of the platinum chromium alloy
(density 9.9 g/cc) is greater than either 316L stainless
steel (density 8.0 g/cc) [24] or cobalt chromium (density
8.4 g/cc - 9.1 g/cc, depending on specific stent platform)
[24] which should enhance visibility of the thinner struts
(Figure 3).
The deliverability of the Element stent may also be
improved by changes in stent architecture, including
thinner struts as well as fewer connectors between
expansion rings (Figure 3). Figure 2B shows a compari-
son of the ex vivo flexibility of the Element stent com-
pared to the Express and Liberté stents. TAXUS
Element is also deployed on a modified Apex balloon
catheter delivery system to improve flexibility and
reduce balloon withdrawal resistance.
The TAXUS Element stent is coated with styrene-b-
isobutylene-b-styrene triblock (SIBS) Translute polymer
loaded with paclitaxel (1 μg/mm
2 loaded drug/stent sur-
face area). The drug-polymer matrix provides controlled
paclitaxel release similar to that of the slow-release
TAXUS Express and TAXUS Liberté stents. The contin-
uous cell geometry of the TAXUS Element stent pro-
vides more uniform drug delivery along the length of
the stent compared to the tandem architecture of the
TAXUS Express stent (Figure 3).
Preclinical Testing
The normal process of healing following stent-induced
injury initially includes the deposition of plasma protein
and/or a thrombotic coating of peristrut fibrin containing
variable amounts of red blood cells, platelets, and leuko-
cytes [25-27]. It has been suggested that delayed arterial
healing following drug-eluting stent implantation is
associated with persistent fibrin deposition and reduced or
delayed endothelialization, and may be predictive of late
stent thrombosis. Stents with thinner struts may be asso-
ciated with less inflammation and injury to the vessel wall
and to become endothelialized more rapidly compared
with thicker strut stents [28]. Preclinical studies demon-
strate that the thinner-strut Element stent is associated
with reduced fibrin deposition and more rapid clearance
of fibrin compared with either the TAXUS Express or
TAXUS Liberté stents (Figure 4) and suggest that the
thin-strut Element stent design may facilitate healing com-
pared to previous generation TAXUS stents.
Appendix B: PERSEUS WH and PERSEUS SV Inclusion and
Exclusion Criteria
Clinical Inclusion Criteria
1. Subject is ≥18 years old
2. Eligible for percutaneous coronary intervention
(PCI)
3. Documented stable angina pectoris or unstable
angina pectoris, or documented silent ischemia
4. Acceptable candidate for coronary artery bypass
grafting (CABG)
5. Left ventricular ejection fraction (LVEF) is ≥30%
6. Subject (or legal guardian) understands the study
requirements and the treatment procedures and pro-
vides written Informed Consent before any study-
specific tests or procedures are performed
7. Subject willing to comply with all specified follow-
up evaluations
Angiographic Inclusion Criteria (Visual Estimate)
1. Target lesion located in native coronary artery
2. Target lesion must be de novo
3. Target lesion diameter stenosis ≥50%
4. Reference vessel diameter (RVD):
PERSEUS WH: ≥2.75 mm to ≤4.0 mm
PERSEUS SV: ≥2.25 mm to <2.75 mm
5. Cumulative target lesion length (area to be treated
must be completely coverable by one study stent)
PERSEUS WH: ≤28 mm
PERSEUS SV: ≤20 mm
6. Target lesion is successfully pre-dilated. Subjects
are enrolled only after successful balloon catheter
pre-dilation of the target lesion.
7. One non-target lesion may be treated in a non-
target vessel
8. Non-target lesion in non-target vessel must be
treated with a commercially available TAXUS stent
if use of drug-eluting stent required.
9. Treatment of a non-target lesion (if performed)
must be deemed a clinical angiographic success,
without requiring use of unplanned additional stent
(s).
10. Treatment must be completed prior to treatment
of target lesion.
Table 2 Nominal Elemental Composition by Weight (%)
Platinum
Chromium
Alloy
316L
Stainless
Steel
L605
(Cobalt
Chromium
Alloy)
MP35N
(Cobalt
Chromium
Alloy)
Iron 37* 64* 3.0 max 1.0 max
Platinum 33 - - -
Cobalt - - 52* 34*
Chromium 18 18 20 20
Nickel 9 14 10 35
Tungsten - - 15 -
Molybdenum 2.63 2.63 - 9.75
Manganese 0.05 max 2.00 max 1.50 0.15 max
Titanium - - - 1.0
*Designated as balance; value calculated from nominal values of other
elements.
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1. Contraindication to ASA, or to both clopidogrel
and ticlopidine
2. Known hypersensitivity to paclitaxel
3. Known allergy to stainless steel
4. Known allergy to platinum
5. Previous treatment of the target vessel with any
anti-restenotic drug-coated or drug-eluting coronary
stent
6. Previous treatment of the target vessel with a bare
metal stent (BMS) within 9 months of the index
procedure
7. Previous treatment of any non-target vessel with
any anti-restenotic drug-coated or drug-eluting cor-
onary stent within 9 months of the index procedure
8. Previous treatment with intravascular brachyther-
apy in the target vessel
9. Planned PCI or CABG post-index procedure
10. Planned or actual target vessel treatment with an
unapproved device, directional or rotational coronary
atherectomy, laser, cutting balloon or transluminal
extraction catheter immediately prior to stent
placement
11. Myocardial infarction (MI) within 72 hours prior
to the index procedure as defined per protocol defi-
nition (see Appendix B)
12. Cerebrovascular accident (CVA) within the past
6 months
13. Cardiogenic shock characterized by systolic pres-
sure < 80 mm Hg and/or central filling pressure >
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Figure 2 Strength and flexibility of the TAXUS Element stent compared to TAXUS Express and TAXUS Liberté stents. (A) Stent integrity,
as measured by an accelerated life test of the bending fatigue of a stent in a simulated overlapped stent configuration, showing number of
bend cycles before stent fracture. The test is conducted by mounting one end of a nominally deployed stent to a fixed mandrel while the other
end is mounted to a mandrel suspended in a flexible membrane. The membrane mounted end of the stent is translated perpendicular to the
longitudinal axis of the stent to impart a repeatable bend in the stent. (B) Conformability - a measure of the torque required to bend the stent
to a specific curvature, which is directly related to flexibility of the stent. Lower required bending moment indicates increased flexibility. N = 15
for each stent type. Bars represent ± 1 standard deviation.
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Page 8 of 1520 mm Hg, or cardiac index < 1.8 liters/minute/m2
or intra-aortic balloon pump or intravenous ino-
tropes are needed to maintain a systolic pressure >
80 mm Hg and a cardiac index > 1.8 liters/minute/
m2
14. Acute or chronic renal dysfunction (creatinine >
2.0 mg/dl or 177 μmol/l)
15. Contraindication to ASA, or to both clopidogrel
and ticlopidine
16. Known hypersensitivity to paclitaxel
17. Known allergy to stainless steel
18. Known allergy to platinum
19. Previous treatment of the target vessel with any
anti-restenotic drug-coated or drug-eluting coronary
stent
20. Previous treatment of the target vessel with a
bare metal stent (BMS) within 9 months of the
index procedure
21. Previous treatment of any non-target vessel with
any anti-restenotic drug-coated or drug-eluting cor-
onary stent within 9 months of the index procedure
22. Previous treatment with intravascular bra-
chytherapy in the target vessel
23. Planned PCI or CABG post-index procedure
24. Planned or actual target vessel treatment with
an unapproved device, directional or rotational cor-
onary atherectomy, laser, cutting balloon or trans-
luminal extraction catheter immediately prior to
stent placement
25. Myocardial infarction (MI) within 72 hours prior
to the index procedure as defined per protocol defi-
nition (see Appendix B)
26. Cerebrovascular accident (CVA) within the past
6 months
27. Cardiogenic shock characterized by systolic pres-
sure < 80 mm Hg and/or central filling pressure >
20 mm Hg, or cardiac index < 1.8 liters/minute/m2
or intra-aortic balloon pump or intravenous ino-
tropes are needed to maintain a systolic pressure >
80 mm Hg and a cardiac index > 1.8 liters/minute/
m2
28. Acute or chronic renal dysfunction (creatinine >
2.0 mg/dl or 177 μmol/l)
29. Any prior true anaphylactic reaction to contrast
agents; defined as known anaphylactoid or other
non-anaphylactic allergic reactions to contrast agents
that cannot be adequately pre-medicated prior to the
index procedure
30. Leukopenia (leukocyte count < 3.5 × 109/liter)
31. Thrombocytopenia (platelet count < 100,000/
mm3)
32. Thrombocytosis (> 750,000/mm3)
33. Active peptic ulcer or active gastrointestinal (GI)
bleeding
34. Current treatment, or past treatment within 12
months of the index procedure, with paclitaxel or
other chemotherapeutic agent(s)
35. Anticipated treatment with paclitaxel or oral
rapamycin during any period in the 9 months after
the index procedure
36. Male or female with known intention to procre-
ate within 9 months after the index procedure
37. Positive pregnancy test within 7 days before the
index procedure, or lactating
38. Life expectancy of less than 24 months due to
other medical conditions
39. Co-morbid condition(s) that could limit the sub-
ject’s ability to comply with study follow-up require-
ments or impact the scientific integrity of the study
40. Currently participating in another investigational
drug or device study
Figure 3 (A) Express, Liberté, and Element stent architecture;
(B) Radiographic comparison of Element and Express stents.
Radiographic image was generated using a General Electric OEC
9800 Digital Imaging System at operating conditions of 51 kV and
11.66 mA. No anatomical simulating phantom was used during
imaging.
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Page 9 of 1541. Any prior true anaphylactic reaction to contrast
agents; defined as known anaphylactoid or other non-
anaphylactic allergic reactions to contrast agents that
cannot be adequately pre-medicated prior to the index
procedure
42. Leukopenia (leukocyte count < 3.5 × 109/liter)
43. Thrombocytopenia (platelet count < 100,000/
mm3)
44. Thrombocytosis (> 750,000/mm3)
45. Active peptic ulcer or active gastrointestinal (GI)
bleeding
46. Current treatment, or past treatment within 12
months of the index procedure, with paclitaxel or
other chemotherapeutic agent(s)
47. Anticipated treatment with paclitaxel or oral
rapamycin during any period in the 9 months after
the index procedure
48. Male or female with known intention to procre-
ate within 9 months after the index procedure
49. Positive pregnancy test within 7 days before the
index procedure, or lactating
50. Life expectancy of less than 24 months due to
other medical conditions
51. Co-morbid condition(s) that could limit the sub-
ject’s ability to comply with study follow-up require-
ments or impact the scientific integrity of the study
52. Currently participating in another investigational
drug or device study
Figure 4 Fibrin deposition around stent struts following TAXUS stent implantation in porcine coronary arteries. Swine coronary arteries
were implanted with overlapping bare metal or TAXUS Express, TAXUS Liberté, or TAXUS Element paclitaxel-eluting stents and examined at 30,
90, and 180 days using light microscopy. Peristrut fibrin deposition was evaluated by study pathologists and scored on a 0-3 scale where 0 = no
visible fibrin, 1 = mild fibrin present, 2 = moderate fibrin present, 3 = extensive fibrin present. Trichrome stained sections, 200× plate
magnification. See Seifert et al., 2007 for more detailed methods [29]. (A) Example specimens at 180 days showing peristrut fibrin deposition
histology. Number of specimens in each category is shown as n/N. (B) Number of specimens with extensive fibrin deposition (score 3) at each
timepoint. There were no significant differences among control bare metal stents in any of the studies.
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Page 10 of 1553. Any prior true anaphylactic reaction to contrast
agents; defined as known anaphylactoid or other
non-anaphylactic allergic reactions to contrast agents
that cannot be adequately pre-medicated prior to the
index procedure
54. Leukopenia (leukocyte count < 3.5 × 109/liter)
55. Thrombocytopenia (platelet count < 100,000/
mm3)
56. Thrombocytosis (> 750,000/mm3)
57. Active peptic ulcer or active gastrointestinal (GI)
bleeding
58. Current treatment, or past treatment within 12
months of the index procedure, with paclitaxel or
other chemotherapeutic agent(s)
59. Anticipated treatment with paclitaxel or oral
rapamycin during any period in the 9 months after
the index procedure
60. Male or female with known intention to procre-
ate within 9 months after the index procedure
61. Positive pregnancy test within 7 days before the
index procedure, or lactating
62. Life expectancy of less than 24 months due to
other medical conditions
63. Co-morbid condition(s) that could limit the sub-
ject’s ability to comply with study follow-up require-
ments or impact the scientific integrity of the study
64. Currently participating in another investigational
drug or device study
Angiographic Exclusion Criteria (Visual Estimate)
1. Target lesion in left main artery, whether pro-
tected or unprotected
2. Target lesion is a chronic total occlusion (TIMI
flow < 1)
3. Target lesion is restenotic
4. Target lesion is located in a saphenous vein graft
or mammary artery graft
5. Target lesion is accessed via saphenous vein graft
or mammary artery graft
6. Target lesion is < 5 mm from bare metal stent
(BMS)
7. Target lesion is < 5 mm from ostium
8. Target lesion is < 5 mm from a side branch vessel
≥ 2.0 mm in diameter (Exceptions: subject may be
enrolled if side branch is 100% occluded or if side
branch is protected with a patent graft)
9. Untreated lesions with ≥ 50% diameter stenosis or
thought to impair flow remaining in target vessel at
a location with ≥ 2.0 mm RVD
10. Target lesion and/or target vessel proximal to the
target lesion is moderately or severely calcified
11. Target lesion and/or target vessel proximal to the
target lesion is severely tortuous
12. Target lesion is located within or distal to a > 60°
bend in the vessel
13. Target lesion with angiographic presence of
probable or definite thrombus
14. Unprotected left main coronary artery disease
15. Protected left main coronary artery disease with
target lesion in LAD or LCx (subject may be
enrolled if only lesion is target lesion in RCA)
Appendix C: PERSEUS WH and PERSEUS SV Definitions
Binary Restenosis
Diameter stenosis >50% at the previously treated lesion
site, including the original treated area and adjacent
proximal and distal QCA analysis segment (see the
Angiographic Core Laboratory Manual within the Site
Manual of Operations).
Clinical Angiographic Success for Non-Target Lesion
Mean lesion diameter stenosis <50% (<30% for stents) in
2 near-orthogonal projections with TIMI 3 flow, as
visually assessed by the physician, without the occur-
rence of prolonged chest pain or ECG changes consis-
tent with myocardial infarction.
Clinical Procedural Success (Visual Estimate)
Mean lesion diameter stenosis <30% in 2 near-orthogo-
nal projections with TIMI 3 flow, as visually assessed by
the physician, without the occurrence of in-hospital
MACE.
Death
Death is divided into 2 categories:
Cardiac death is defined as death due to any of the
following:
1. Acute myocardial infarction
2. Cardiac perforation/pericardial tamponade
3. Arrhythmia or conduction abnormality
4. Cerebrovascular accident through hospital dis-
charge or cerebrovascular accident suspected of
being related to the procedure
5. Death due to complication of the procedure,
including bleeding, vascular repair, transfusion reac-
tion, or bypass surgery
6. Any death in which a cardiac cause cannot be
excluded
Non-cardiac death is defined as a death not due to
cardiac causes (as defined above).
% Diameter Stenosis
Angiographic % diameter stenosis (% DS) was defined as
(1-[MLD/RVD])×100.
Late Loss
Post-procedure MLD minus follow-up MLD as deter-
mined by quantitative angiography.
Major Adverse Cardiac Events (MACE)
An event of MI and/or an event resulting in TVR and/
or cardiac death are considered MACE events for this
study.
Myocardial Infarction
Myocardial Infarction will be defined as either:
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Page 11 of 151. Q-wave MI: Development of new (i.e., not present
on the subject’s ECG before allocation) pathological
Q - w a v e si n2o rm o r el e a d sl a s t i n g≥ 0.04 seconds
with post procedure CK-MB levels elevated above
normal.
2. Non-Q-Wave MI: De novo elevation of CK Total
levels > 2.0 × ULN without the presence of new Q-
waves (not present on the subject’s ECG before allo-
cation). If CK-MB performed, it must be positive.
For subjects undergoing bypass surgery, a periopera-
tive MI will be defined as (a) Total CK-MB > 5× upper
limits of local laboratory normal, or (b) Presence of new
pathologic Q waves (as defined above).
Stent Thrombosis
NOTE: Data will be collected which will allow for
reporting per Boston Scientific’sH i s t o r i c a l( T A X U SI V
and V) stent thrombosis definition as well as the Aca-
demic Research Consortium stent thrombosis definition
[12].
Boston Scientific Historical (TAXUS IV and V [1,7])
Stent Thrombosis Definition:
The occurrence of any of the following:
1. Clinical presentation of acute coronary syndrome
with angiographic evidence of stent thrombosis:
￿ Angiographic documentation of acute complete
occlusion (TIMI flow 0 or 1) of the treated area in a
previously successfully treated artery (TIMI flow 2 to
3 immediately after stent placement and diameter
stenosis ≤ 30%) and/or
￿ Angiographic documentation of a flow limiting
thrombus within or adjacent to the successfully trea-
ted lesion.
2. Acute MI in the distribution of the treated vessel.
3. Cardiac death within the first 30 days post index
procedure (without other obvious cause) is consid-
ered a surrogate for stent thrombosis when angio-
graphy is not available.
Stent thrombosis will be classified as follows:
1. “Confirmed stent thrombosis” for the description
of above events with angiographic evidence.
2. “Presumed stent thrombosis” for the description
of above events in the absence of an angiography (i.
e., such as in the case of death without autopsy).
Academic Research Consortium Definition:
Stent thrombosis will also be defined per the Definite,
Probable, and Possible definitions described in Cutlip
et al., 2007 [12].
Timing:
Acute stent thrombosis: 0 - 24 hours post stent
implantation
Subacute stent thrombosis: >24 hours - 30 days post
stent implantation
Late stent thrombosis: >30 days - 1 year post stent
implantation
Very late stent thrombosis: >1 year post stent
implantation
Target Lesion Failure (TLF)
Any ischemia-driven revascularization of the target
lesion (TLR), MI (Q-wave and non-Q-wave) related to
the target vessel, or (cardiac) death related to the target
vessel.
For the purposes of this protocol, if it cannot be
determined with certainty whether MI or death was
related to the target vessel, it will be considered TLF.
Target Lesion Revascularization (TLR)
Target Lesion Revascularization is defined as any ische-
mia-driven repeat percutaneous intervention (to improve
blood flow) of the successfully treated target lesion or
bypass surgery of the target vessel with a graft distally
to the successfully treated target lesion.
A target lesion revascularization will be considered as
ischemia-driven if the target lesion diameter stenosis is
≥ 50% by QCA and there is presence of clinical or func-
tional ischemia which cannot be explained by other cor-
onary or graft lesions. Clinical or functional ischemia is
any of the following:
1. The subject has a positive functional study corre-
sponding to the area served by the target lesion
2. The subject has ischemic ECG changes at rest in a
distribution consistent with the target vessel
3. The subject has ischemic symptoms referable to
the target lesion.
A target lesion revascularization will be considered as
ischemia-driven if the lesion diameter stenosis is ≥ 70%
by QCA even in the absence of clinical or functional
ischemia.
Target Vessel Failure (TVF)
Any ischemia-driven revascularization of the target ves-
sel, MI (Q- and non-Q-wave) related to the target ves-
sel, or death related to the target vessel.
For the purposes of this protocol, if it cannot be
determined with certainty whether MI or death was
related to the target vessel, it will be considered TVF.
Target Vessel Revascularization (TVR)
Presence of any Target Lesion Revascularization or Tar-
get Vessel Revascularization Remote.
Target Vessel Revascularization, Remote (TVR, Non-TLR)
Target Vessel Revascularization, Non-TLR is defined as
any ischemia-driven repeat percutaneous intervention
(to improve blood flow) or bypass surgery of not pre-
viously existing lesions ≥ 50% by QCA in the target ves-
sel, excluding the target lesion.
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Page 12 of 15A target vessel revascularization will be considered
ischemia-driven if the target vessel diameter stenosis is
≥ 50% by QCA and any of the following are present:
1. The subject has a positive functional study corre-
sponding to the area served by the target vessel
2. The subject has ischemic ECG changes at rest in a
distribution consistent with the target vessel
3. The subject has ischemic symptoms referable to
the target vessel.
A target vessel revascularization will also be consid-
ered as ischemia-driven if the lesion diameter stenosis is
≥ 70% even in the absence of clinical or functional
ischemia.
Technical Success
Technical success is defined as successful delivery and
deployment of the study stent to the target vessel, with-
out balloon rupture or stent embolization.
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